Manufacturer of Controlled Substances, Notice of Application; Alltech Associates, Inc., 12103 [2013-03919]

Download as PDF 12103 Federal Register / Vol. 78, No. 35 / Thursday, February 21, 2013 / Notices Drug Schedule erowe on DSK2VPTVN1PROD with NOTICES Aminorex (1585) ........................... Alpha-ethyltryptamine (7249) ....... Lysergic acid diethylamide (7315) Tetrahydrocannabinols (7370) ..... 4-Bromo-2,5dimethoxyamphetamine (7391). 4-Bromo-2,5dimethoxyphenethylamine (7392). 2,5-Dimethoxyamphetamine (7396). 3,4-Methylenedioxyamphetamine (7400). N-Hydroxy-3,4methylenedioxyamphetamine (7402). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4Methylenedioxymethamphetamine (MDMA) (7405). Psilocybin (7437) .......................... 5-Methoxy-N,Ndiisopropyltryptamine (7439). 1-[1-(2Thienyl)cyclohexyl]piperidine (TCP) (7470). N-Benzylpiperazine (BZP) (7493) Heroin (9200) ............................... Normorphine (9313) ..................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Nabilone (7379) ............................ 1-Phenylcyclohexylamine (7460) Phencyclidine (7471) .................... Cocaine (9041) ............................. Codeine (9050) ............................. Ecgonine (9180) ........................... Levomethorphan (9210) ............... Levorphanol (9220) ...................... Meperidine (9230) ........................ Metazocine (9240) ........................ Methadone (9250) ........................ Morphine (9300) ........................... Thebaine (9333) ........................... Levo-alphacetylmethadol (9648) .. Remifentanil (9739) ...................... Carfentanil (9743) ......................... Fentanyl (9801) ............................ I I I I I 14:47 Feb 20, 2013 BILLING CODE 4410–09–P I DEPARTMENT OF JUSTICE I Drug Enforcement Administration I Manufacturer of Controlled Substances; Notice of Application; GE Healthcare I Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 31, 2012, GE Healthcare, 3350 North Ridge Avenue, Arlington Heights, Illinois 60004–1412, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in schedule II. The company plans to manufacture a radioactive product to diagnose Parkinson’s disease; and to manufacture a bulk investigational new drug (IND) for clinical trials. Any other such applicant, and any person who is presently registered with DEA to manufacture such a substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 22, 2013. I I I I I I I I II II II II II II II II II II II II II II II II II II II Jkt 229001 Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug [FR Doc. 2013–03893 Filed 2–20–13; 8:45 am] The company plans to manufacture reference standards. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 22, 2013. VerDate Mar<15>2010 Dated: February 8, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Dated: February 8, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–03895 Filed 2–20–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances, Notice of Application; Alltech Associates, Inc. Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 19, 2012, Alltech Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made application to the Drug PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 5-Methoxy-N–Ndimethyltryptamine (7431). 2C–E (2-(2,5-Dimethoxy-4ethylphenyl)ethanamine) (7509). 2C–H (2-(2,5Dimethoxyphenyl)ethanamine) (7517). 2C–T–4 (2-(4-isopropylthio)-2,5dimethoxyphenyl) ethanamine) (7532). Schedule I I I I The company plans to manufacture high purity drug standards used for analytical applications only in clinical, toxicological, and forensic laboratories. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 22, 2013. Dated: February 8, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–03919 Filed 2–20–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration; Cody Laboratories, Inc. By Notice dated November 1, 2012, and published in the Federal Register on November 9, 2012, 77 FR 67398, Cody Laboratories, Inc., ATTN: Richard Asherman, 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Dihydromorphine (9145) ................ Amphetamine (1100) ...................... Methamphetamine (1105) .............. E:\FR\FM\21FEN1.SGM 21FEN1 Schedule I II II

Agencies

[Federal Register Volume 78, Number 35 (Thursday, February 21, 2013)]
[Notices]
[Page 12103]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-03919]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances, Notice of Application; 
Alltech Associates, Inc.

    Pursuant to Sec.  1301.33(a), Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on November 19, 2012, Alltech 
Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made 
application to the Drug Enforcement Administration (DEA) to be 
registered as a bulk manufacturer of the following basic classes of 
controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
5-Methoxy-N-N-dimethyltryptamine (7431)....  I
2C-E (2-(2,5-Dimethoxy-4-                    I
 ethylphenyl)ethanamine) (7509).
2C-H (2-(2,5-Dimethoxyphenyl)ethanamine)     I
 (7517).
2C-T-4 (2-(4-isopropylthio)-2,5-             I
 dimethoxyphenyl) ethanamine) (7532).
------------------------------------------------------------------------

    The company plans to manufacture high purity drug standards used 
for analytical applications only in clinical, toxicological, and 
forensic laboratories.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than April 22, 2013.

     Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-03919 Filed 2-20-13; 8:45 am]
BILLING CODE 4410-09-P